


Available online on 15.10.2020 at <http://ajprd.com>

# Asian Journal of Pharmaceutical Research and Development

Open Access to Pharmaceutical and Medical Research

© 2013-20, publisher and licensee AJPRD, This is an Open Access article which permits unrestricted non-commercial use, provided the original work is properly cited



Open Access

Review Article

## A Review: Parkinson's disease

**Pallavi S Mhaske\*, Shrikrushna Subhash Unhale, Vijaya B Mehetre, Kanchan P Pandhare, Vaishnavi U Petkar, Kailash R. Biyani**

Anuradha College of Pharmacy, chikhli, Dist -Buldana (MS) India 443201

### ABSTRACT

Parkinson's disease (PD), or simply Parkinson's, is a long-term degenerative disorder of the central nervous system that mainly affects the motor system. Parkinson's sickness (PD) has a place with a gathering of conditions called motor system issues, which cause unintended or wild developments of the body. The precise cause of PD is unknown, but some cases are hereditary while others are thought to occur from a combination of genetics and environmental factors that trigger the disease. In PD, brain cells become damaged or die in the part of the brain that produces dopamine--a chemical needed to produce smooth, purposeful movement.

Parkinson's ailment is a dynamic sensory system issue that influences development. Indications start progressively, in some cases beginning with a scarcely observable quake in only one hand. Quakes are normal, however the confusion additionally ordinarily causes solidness or easing back of development. In this review article we include Introduction, How to Parkinson's disease occurs, mechanism, pathophysiology, Diagnosis, treatment, medication, causes, symptoms of Parkinson's disease.

**Keywords:** Parkinson's disease (PD), Motor system, pathophysiology, diagnosis, treatment.

**ARTICLE INFO:** Received 02 July 2020; Review Completed 15 Sept. 2020; Accepted 07 Oct. 2020; Available online 15 Oct. 2020



#### Cite this article as:

Mhaske P S, Unhale SS, Mehetre VB, Pandhare KP, Petkar VU, Biyani KR, A Review: Parkinson's disease, Asian Journal of Pharmaceutical Research and Development. 2020; 8(5):109-113.

DOI: <http://dx.doi.org/10.22270/ajprd.v8i5.833>

\*Address for Correspondence:

Pallavi S Mhaske, A Review: Parkinson's disease

### INTRODUCTION:

Parkinson's disease is a long-term (chronic) neurological condition that affects around 8,000 people in Ireland. It is named after Dr James Parkinson, who originally recognized it in 1817. Parkinson's infection influences the way the mind co-ordinates body developments, including strolling, talking and composing<sup>1</sup>. Parkinson's illness is a confusion that influences little locales in the cerebrum that control development, stance and equalization. It is a complex disease that has many different symptoms, so that not everyone with the condition suffers from the same problems.<sup>2</sup>

More than 1 million people in the United States have Parkinson disease (PD), more than are diagnosed as having multiple sclerosis, amyotrophic lateral sclerosis, muscular dystrophy, and my-asthenia gravis combined. PD affects approximately 1 in 100 Americans older than 60 years. It

loads patients, their consideration accomplices, and the general healthcare system.<sup>3</sup> This article audits the study of disease transmission, clinical highlights, putative ecological hazard and defensive components, neuropathological angles, heterogeneity, clinical administration, and late examinations with respect to hereditary qualities and PD. The article suggests that based on new research, the prevalence of PD varies in different regions of the United States.<sup>4</sup> Some progress has been made in identifying the risk and protective factors of PD, and a newly emphasized area of study in PD is genetics. Patient care proposals, in light of American Academy of Neurology practice guidelines, are laid out to show the condition of contemporary clinical administration of PD and related disorders.<sup>5</sup>

#### How the Parkinson's disease occurs

In Parkinson's disease, certain nerve cells (neurons) in the cerebrum step by step separate or pass on. Huge numbers of

the manifestations are because of lost neurons that produce a compound courier in your mind called dopamine.<sup>6</sup> At the point when dopamine levels decline, it causes anomalous

mind movement, prompting side effects of Parkinson's disease.<sup>7</sup>

## Mechanisms of Parkinson's Disease




Figure: 1 Mechanism of Parkinson's disease

## PATHOPHYSIOLOGY

The pathophysiology of Parkinson's infection is demise of dopaminergic neurons because of changes in biological activity in the cerebrum regarding Parkinson's illness (PD). There are a few proposed instruments for neuronal demise in PD; be that as it may, not every one of them are surely

known.<sup>8</sup> Five proposed mechanisms systems for neuronal demise in Parkinson's Disease remember protein total for Lewy bodies, interruption of autophagy, changes in cell digestion or mitochondrial capacity, neuroinflammation, and blood-mind blood-brain barrier (BBB) breakdown resulting in vascular leakiness.<sup>9</sup>




Figure: 2 A brain without and with Parkinson's Disease compared in Substantia Nigra

**Diagnosis:-**

There is no “one way” to analyze Parkinson's disease (PD). Notwithstanding, there are different manifestations and indicative tests utilized in blend. Making an exact determination of Parkinson's - especially in its beginning phases- is troublesome, however a talented expert can arrive at a contemplated resolution that it is PD.<sup>10</sup> Remember that two of the four primary side effects must be available over some undefined time frame for a neurologist to think about a PD analysis:

- Shaking or tremor
- Slowness of movement, called bradykinesia
- Stiffness or rigidity of the arms, legs or trunk
- Trouble with balance and possible falls, also called postural instability

Regularly, a Parkinson's diagnosis is first made by an internist or family doctor. Numerous individuals look for an extra supposition from a nervous system specialist with experience and explicit preparing in the evaluation and treatment of PD .<sup>11</sup>

**Treatment**

Parkinson's disease can't be relieved, however drugs can help control your side effects, frequently significantly. In some later cases, surgery may be advised.<sup>12</sup>

Your primary care physician may likewise suggest way of life changes, particularly progressing oxygen consuming activity. At times, exercise based recuperation that centers around equalization and extending additionally is significant. A speech-language pathologist may help improve your speech problems.<sup>13</sup>

**Medications**

Medications may assist you with overseeing issues with strolling, development and tremor. These medications increase or substitute for dopamine.<sup>14</sup> Individuals with Parkinson's disease has low cerebrum dopamine concentrations. In any case, dopamine can't be given straightforwardly, as it can't enter your cerebrum. You may have huge improvement of your indications subsequent to starting Parkinson's disease treatment. After some time, be that as it may, the advantages of medications much of the time reduce or turn out to be less predictable. You can typically still control your indications genuinely well.<sup>15</sup>

**Medications your doctor may prescribe include:**

1. Carbidopa-levodopa.
2. Carbidopa-levodopa infusion.
3. Dopamine agonists.
4. MAO B inhibitors
5. Catechol O-methyltransferase (COMT) inhibitors.
6. Anticholinergics.
7. Amantadine.

**Symptoms**

Parkinson's disease affects the nerve cell in the midbrain that produced dopamine

**Parkinson's symptoms****Initial symptoms**

A. Expression less face

**Tremor****Symptoms no hands and legs**

Can occur at rest in the hands limbs or can be postural

**Muscular**

Hardened muscles, trouble standing trouble strolling, with bodily movement involuntary movement, muscle unbending nature, issue with coordination, muscular muscle compression, slow real development, or moderate rearranging stride.<sup>16,17</sup>

**Sleep**

Early awakening nightmares, restless sleep, or sleep disturbances

**Whole body**

Fatigue, dizziness, poor, restlessness, balance

**Cognitive**

Amnesia, disarray at night hours dementia or trouble thinking and understanding

**Speech**

Difficulty speaking, soft speech or voice box spasms

**Nasal**

Distorted sense of smell or loss of smell

**Urinary**

Dribbling of urine or leaking of urine

**Mood**

Anxiety or a pathy

**Facial**

Jaw stiffness or reduced facial expression

**Also common**

Clear gaze, constipation depression, trouble gulping slobbering, falling trepidation of falling misfortune interestingly affectability, neakfhtness little handroring, shaking, accidental composition, or weight reduction.<sup>18,19</sup>

**Causes of parkinson's disease**

Genetics,  
Environment  
Lewy bodies  
Loss of dopamine  
Age and gender

Occupation

### Genetic

Some studies suggests that genes play a role in the development of parkinson's

An estimated is percent of people with parkinson's have a

Family history of the condition <sup>20</sup>

### Environment

These include pesticides such as insecticide herbicides,

And fungicides

It also possible that agent arrange exposure may be linked

To parkinson's

### Lewy bodies

Lewy bodies are abnormal clumps of protein found in the brain

Steam of people with parkinson's disease

Cluster of lewy bodies cause the brain to degenerate over time,

This cause problem with motor coordination in people with parkinson's disease . <sup>21</sup>

### Loss of dopamine

Dopamine is neurotransmitter chemical that aid's in passing message between different section of the brain . <sup>22</sup>

The cells that produce dopamine are damaged in people with parkinson's disease.

Without an adequate supply of dopamine the brain is unable to properly send and receive. <sup>23</sup>

Massages this distribution affect the body ability to coordinate movement, it can cause problem with walking and balance . <sup>24</sup>

### Age and gender

Aging also play a role in parkinson's disease advanced age is the most significant risk factor for developing parkinson's disease

Scientists believe that brain and dopamine function begin to decline as the body ages this make a person . <sup>25</sup>

More suceptiole to parkinson's diseases

Gender also play in role in parkinson's disease man is more susceptible to developing parkinson's disease the women . <sup>26</sup>

### Risk factor of parkinson's disease

Age and sex, genetic factor, head trauma

Exposure to chemical, medication and drug

Impact of smoking <sup>27</sup>

Age

In a most people who have parkinson's disease, symptoms becomes noticeable at the age of 60 yr old

However in 5-10 % of causes they appear earlier, when parkinson's disease devolve before the age of 50 yr . This is called early onset parkinson's disease <sup>28</sup>

### Genetic factor and family history

A person who have close relative, such as a siblings or parent when parkinson's disease saliently higher risk of developing it. Compar with other

The other are" sporadic "there is currently on way to predict that they will occurs

Autosomal dominant<sup>29</sup>

Autosomal recessive

Risk factor modifiers gens

### Exposure of chemical

People who work in certain profession may have higher chance to develop to parkinson's disease, because of exposure to certain chemical. <sup>30</sup>

### Toxic

There is some evidence that exposure to certain toxic can increasing the chance of developing parkinson's disease according to the parkinson's disease foundation. <sup>31,32</sup>

- Herbicides and pesticides
- They may include
- Some herbicides, such as paraquat
- Fungicides, such as maneb
- Insecticide, such as colourless, oderless, rotenone
- Pesticides

### Impact of smoking

Interesting, who smoke cigarette appear to have a smaller chance of developing PD than those who do not

This does not mean that people should smoke in order to stave off PD, because smoking is responsible for a host of unwanted health problems <sup>33</sup>

### CONCLUSION:

Parkinson's disease is one of the most common neurodegenerative diseases affecting the aging population and is associated with an increased morbidity and mortality. Awareness of the disease manifestations, the treatments, and the progressive long-term course of the disease is necessary for the optimal management of the cases. Tremendous progress has been made in understanding the neuropathology of PD and its progression throughout the nervous system. However, none of these treatments is curative. PD remains a progressive disorder that eventually causes severe disability due to the increasing severity of treatment-resistant motor problems and non-motor symptoms. Modifying factors that lead to the disease progression and in further delaying its disability are the key unmet needs to be addressed by the current and future research efforts.



## REFERENCES:

- Koller WC, Busenbark KL. Essential tremor. In: Watts RL, Koller WC, eds. Movement disorders New York: McGraw-Hill, 1997:365-85.
- Ben-Shlomo Y. The epidemiology of Parkinson's disease. In: Quinn NP, ed. Parkinsonism London: Bailliere-Tindall, 1997:55-68.
- National Institute for Health and Clinical Excellence. Parkinson's disease: diagnosis and management in primary and secondary care London: NICE, 2006. (<http://guidance.nice.org.uk/CG35>)
- Bennett DA, Beckett LA, Murray AM, Shannon KM, Goetz CG, Pilgrim DM, et al. Prevalence of parkinsonian signs and associated mortality in a community population of older people. *N Engl J Med* 1996; 334:71-6.
- Gibb WRG, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. *J NeurolNeurosurg Psychiatry* 1988; 51:745-52.
- Meara J, Bhowmick B, Hobson P. Accuracy of diagnosis in patients with presumed Parkinson's disease. *Age Ageing* 1999; 28:99-102.
- Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. *J Neurol Neurosurg Psychiatry* 1992; 55:181-4.
- Jankovic J, Rajput A, McDermott M, Perl D, Parkinson Study Group. The evolution of diagnosis in early Parkinson disease. *Arch Neurol* 2000; 57:369-72.
- Twelves, D., Perkins, K. S. & Counsell, C. Systematic review of incidence studies of Parkinson's disease. *Mov. Disord.* 2003; 18:19-31.
- Savica, R., Grossardt, B. R., Bower, J. H., Ahlskog, J. E. & Rocca, W. A. Incidence and pathology of synucleinopathies and tauopathies related to parkinsonism. *JAMA Neurol.* 2013; 70:859-866.
- Van Den Eeden, S. K. et al. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. *Am. J. Epidemiol.* 2003; 157:1015-1022.
- Pringsheim, T., Jette, N., Frolkis, A. & Steeves, T. D. The prevalence of Parkinson's disease: a systematic review and meta-analysis. *Mov. Disord.* 2014; 29; 1583:1590.
- Pinter, B. et al. Mortality in Parkinson's disease: a 38-year follow-up study. *Mov. Disord.* 2015; 30:266-269.
- Kasper DL, et al., eds. Parkinson's disease and other movement disorders. In: Harrison's Principles of Internal Medicine. 19th ed. New York, N.Y.: McGraw-Hill Education; 2015. <http://accessmedicine.mhmedical.com>. Accessed May. 2015; 292018.
- Parkinson's disease: Hope through research. National Institute of Neurological Disorders and Stroke. <https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Hope-Through-Research/Parkinsons-Disease-Hope-Through-Research>. Accessed May. 29, 2018.
- <https://www.nhs.uk/conditions/parkinsons-disease/causes/>
- Paisan-Ruiz, C., Jain, S., Evans, E. W., Gilks, W. P., Simon, J., van der Brug, M., et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. *Neuron*. 2004; 44:595-600. doi: 10.1016/j.neuron.2004.10.02
- Park, G., Tan, J., Garcia, G., Kang, Y., Salvesen, G., and Zhang, Z. Regulation of histone acetylation by autophagy in parkinson disease. *J. Biol. Chem.* 2016; 291:531-3540. doi: 10.1074/jbc.M115.675488
- Parkinson, J. An essay on the shaking palsy. *J. Neuropsychiatry Clin. Neurosci.* 2017 14, 223-236. doi: 10.1176/jnp.14.2.223
- Pastor, P., Ezquerro, M., Munoz, E., Martí, M. J., Blesa, R., Tolosa, E., et al. Significant association between the tau gene A0/A0 genotype, and Parkinson's disease. *Ann Neurol.* 2000; 47:242-245. doi: 10.1002/1531-8249(200002)47:2<242::AID-ANA16>3.0.CO
- Pihlstrom, L., Berge, V., Rengmark, A., and Toft, M. (2015). Parkinson's disease correlates with promoter methylation in the alpha-synuclein gene. *Mov. Disord. J. Mov. Disord. Soc.* 2015; 30:577-580. doi: 10.1002/mds.26073
- Politis, M., Wu, K., Molloy, S., Bain, P. G., Chaudhuri, K. R., and Piccini, P. Parkinson's disease symptoms: the patient's perspective. *Mov. Disord. Off. J. Mov. Disord. Soc.* 2010; 25:1646-1651. doi: 10.1002/mds.23135
- Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. *Science.* 1997; 276:2045-2047. doi: 10.1126/science.276.5321.2045
- Pont-Sunyer, C., Tolosa, E., Caspell-Garcia, C., Coffey, C., Alcalay, R. N., Chan, P., et al. The prodromal phase of leucine-rich repeat kinase 2-associated Parkinson disease: clinical and imaging Studies. *Mov. Disord.* 2017; 32:726-738. doi: 10.1002/mds.2696
- Postuma, R. B., and Berg, D. Advances in markers of prodromal Parkinson disease. *Nat. Rev. Neurol.* 2016; 12:622-634. doi: 10.1038/nrneurol.2016.152
- Postuma, R. B., Gagnon, J.-F., Pelletier, A., and Montplaisir, J. Y. (2017). Insomnia and somnolence in idiopathic RBD: a prospective cohort study. *NPJ Park. Dis.* 3:9. doi: 10.1038/s41531-017-0011-7
- Proukakis, C., Dudzik, C. G., Brier, T., MacKay, D. S., Cooper, J. M., Millhauser, G. L., et al. A novel  $\alpha$ -synuclein missense mutation in Parkinson disease. *Neurology.* 2013; 80:1062-1064. doi: 10.1212/WNL.0b013e31828727ba
- Rodríguez-Nogales, C., Garbayo, E., Carmona-Abellán, M. M., Luquin, M. R., and Blanco-Prieto, M. J. Brain aging and Parkinson's disease: new therapeutic approaches using drug delivery systems. *Maturitas* 2016; 84:25-31. doi: 10.1016/j.maturitas.2015.11.009
- Rodríguez-Oroz, M. C., Obeso, J. A., Lang, A. E., Houeto, J. L., Pollak, P., Reñancón, S., et al. Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. *Brain.* 2005; 128: 2240-2249. doi: 10.1093/brain/awh571
- Rosin B, Slovik M, Mitelman R, Rivlin-Etzion M, Haber S N, Israel Z, et al. Closed-loop deep brain stimulation is superior in ameliorating Parkinsonism. *Neuron* 2011; 72:370-384.
- Sakakibara, R., Tateno, F., Kishi, M., Tsuyusaki, Y., Terada, H., and Inaoka, T. MIBG myocardial scintigraphy in pre-motor Parkinson's disease: a review. *Parkinsonism Relat. Disord.* 2014; 20:267-273. doi: 10.1016/j.parkreldis.2013.11.001
- <https://www.medicalnewstoday.com/articles/323440#age-and-sex>
- <https://g.co/kgs/sQ7oNL>